References
- Weyand C. M., Goronzy J. J. Medium‐ and large‐vessel vasculitis. N Engl J Med 2003; 349: 160–9
- Ferraccioli G. F., Di Poi E., Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica–giant cell arteritis. State of the art and perspectives. Clin Exp Rheumatol 2000; 18((Suppl 20))58–60
- Hoffman G. S., Cid M. C., Hellmann D. B., Guillevin L., Stone J. H., Schousboe J., et al. A multicentre, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309–18
- Jover J. A., Hernandez‐Garcia C., Morado I. C., Vargas E., , Jover J. A., Hernandez‐Garcia C., Morado I. C., Vargas E., Banares A., Fernandez‐Gutierrez B, et al. Combined treatment of giant‐cell arteritis with methotrexate and prednisone: a randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 2001; 134: 106–14
- Yocum D. Immunological actions of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 32((Suppl))38–41
- Kenichirou T., Ryuichi A., Tomoki I., Michihiko M., Masashi T., Shirou F. Immunomulatory effects of cyclosporine A on human peripheral blood dendritic cell subsets. Immunology 2003; 108: 321–31
- Schaufelberger C., Andersson R., Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis. Results of an open, controlled, randomized trial. Br J Rheumatol 1998; 37: 464–5
- Hunder G. G., Bloch D. A., Michel B. A., Stevens M. B., Arend W. P., Calabrese L. H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–8
- Zachariae H. Renal toxicity of long‐term cyclosporin. Scand J Rheumatol 1999; 28: 65–8